(MedPage Today) -- Data from a third phase III trial of icatibant (Firazyr), an investigational drug for treating hereditary angioedema (HAE) attacks, were good enough to justify the drug's approval, FDA staff indicated in a briefing document made public before a Thursday advisory committee meeting.